...
首页> 外文期刊>Journal of Immune Based Therapies Vaccines >Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults
【24h】

Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults

机译:牛分枝杆菌卡介苗Moreau Rio de Janeiro(RDJ)在健康成年人中对口服BCG疫苗的体液免疫反应的调节

获取原文

摘要

Background Oral administration of BCG was the route initially used by Calmette and Guérin, but was replaced by intradermal administration in virtually all countries after the Lubeck accident. However, Brazil continued to administer oral BCG Moreau RDJ, which was maintained until the mid-1970s when it was substituted by the intradermal route. Although BCG vaccination has been used in humans since 1921, little is known of the induced immune response. The aim of this study was to analyse immunological responses after oral vaccination with M. bovis BCG Moreau RDJ. Methods This study in healthy volunteers has measured cellular and humoral aspects of the immunological response to oral M. bovis BCG Moreau RDJ in Rio de Janeiro, Brazil. T-cell trafficking and Th1 and Th2 cytokine responses are described, as well as isotype-specific antibody production using novel techniques. Results Oral immunisation has no adverse effects. We have shown that there are cellular and humoral immunological responses after oral immunisation. Oral revaccination does not induce a positive skin test in responsive individuals and multiple booster orally was able to induce modulation in humoral immunological responses (switch from IgG to IgA) in previously immunised subjects and incapable of inducing tolerance. In contrast, the cellular immune response does not differ between vaccinated individuals with positive and negative skin test reactions. Conclusion All subjects, including those who did not respond to the skin test at study commencement, were capable of mounting humoral and cellular immune response to the antigens tested.
机译:背景BCG的口服给药是Calmette和Guérin最初使用的途径,但在吕贝克事故发生后,几乎所有国家都通过皮内给药来替代。但是,巴西继续口服BCG Moreau RDJ口服液,该溶液一直维持到1970年代中期,之后被皮内途径替代。尽管自1921年以来就已在人中使用BCG疫苗接种,但对诱导的免疫反应知之甚少。这项研究的目的是分析口服牛分枝杆菌BCG Moreau RDJ疫苗后的免疫反应。方法这项针对健康志愿者的研究测量了巴西里约热内卢对牛牛分枝杆菌BCG Moreau RDJ免疫反应的细胞和体液方面。描述了T细胞运输以及Th1和Th2细胞因子反应,以及使用新技术产生的同种型特异性抗体。结果口服免疫无不良反应。我们已经证明口服免疫后存在细胞和体液免疫反应。口服疫苗接种不会在有反应的个体中引起皮肤试验阳性,并且多次加强口服治疗能够在先前免疫的受试者中诱导体液免疫反应的调节(从IgG转换为IgA),并且无法诱导耐受性。相反,在具有阳性和阴性皮肤测试反应的接种个体之间,细胞免疫反应没有差异。结论所有受试者,包括在研究开始时对皮肤试验无反应的受试者,均能够对所测抗原产生体液和细胞免疫应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号